InsiderTrades.com logo
M Milne Jr net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

M Jr Biography and Net Worth

Director of Amylyx Pharmaceuticals

Dr. Milne began serving as a director of Amylyx in 2015. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. George M. Milne, Jr., Ph.D. became a Radius Venture Partner in 2002. Milne has served on the Board of Directors at many different companies and organizations including currently Charles River Laboratories, Mettler-Toledo, Inc., BioStorage Technologies Inc., Draper Laboratory, the Sea Research Foundation, and the New York Botanical Garden. During his notable career, Milne has received a variety of honors, including an award from Yale University for lifetime contributions to commerce, innovation or education, the Connecticut College medal, and the distinguished citizen award from Big Brothers/Big Sisters. Dr. Milne received a B.S. in Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.

What is M Milne Jr's net worth?

The estimated net worth of M Milne Jr is at least $23.65 million as of October 5th, 2026. Jr owns 782,881 shares of Amylyx Pharmaceuticals stock worth more than $23,650,835 as of November 10th. This net worth approximation does not reflect any other assets that Jr may own. Learn More about M Milne Jr's net worth.

How do I contact M Milne Jr?

The corporate mailing address for Jr and other Amylyx Pharmaceuticals executives is 55 Cambridge Parkway, Suite 6w, Cambridge, MA, 02142. Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on M Milne Jr's contact information.

Has M Milne Jr been buying or selling shares of Amylyx Pharmaceuticals?

During the past quarter, M Milne Jr has sold $831,000.00 of Amylyx Pharmaceuticals stock. Most recently, M Milne Jr sold 30,000 shares of the business's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $27.70, for a transaction totalling $831,000.00. Following the completion of the sale, the director now directly owns 782,881 shares of the company's stock, valued at $21,685,803.70. Learn More on M Milne Jr's trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), Karen Firestone (Director), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 8,100 shares worth more than $100,845.00. In the last year, insiders at the sold shares 11 times. They sold a total of 233,157 shares worth more than $4,212,865.41. The most recent insider tranaction occured on October, 5th when Director M Milne Jr sold 30,000 shares worth more than $831,000.00. Insiders at Amylyx Pharmaceuticals own 10.9% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 10/5/2026.

M Milne Jr Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/5/2026Sell30,000$27.70$831,000.00782,881View SEC Filing Icon  
9/3/2024Buy100,000$2.20$220,000.00858,571View SEC Filing Icon  
3/16/2023Sell35,000$31.89$1,116,150.00862,021View SEC Filing Icon  
See Full Table

M Milne Jr Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows M Milne Jr's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
Read More

Today's Range

Now: $30.21
Low: $28.76
High: $30.32

50 Day Range

MA: $29.91
Low: $26.34
High: $34.49

2 Week Range

Now: $30.21
Low: $10.83
High: $41.14

Volume

1,297,563 shs

Average Volume

1,297,575 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A